| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WILTSHIRE, U.K.—Speciality pharmaceutical company Alliance Pharma plc announced June 7 that its wholly owned subsidiary AlliancePharmaceuticals Ltd. has acquired all existing rights toSyntometrine , a drug for which it already owned rights in the United Kingdom, from Novartis AG for $11.5 million. 
 
Syntometrine is an obstetric drug used in the final stage of labor, and Novartisand its affiliates have been selling the drug in a number of countries worldwide, including Australia,South Africa, Malaysia and New Zealand. In the 12 months to March 2013the total sales of Syntometrine by the Novartis Group were $3.2million, and the gross margin generated was $2.8 million. 
 
"We are delighted to acquire these significant overseas rights toSyntometrine, a product we already know well through selling it in theUK for many years," said John Dawson, CEO of Alliance Pharma. "Although there will be some costs of operating thenew distributorships, the acquisition will be immediately earningsenhancing and it fits well with our strategy of increasing Alliance'sinternational sales."
 
Allianceexpects to have annual distribution and operating costs of approximately£500,000 associated with these new territories. 
 
The $11.5million consideration is being funded from existing cash and bankfacilities.
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue